-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Today, Selecta Biosciences announced that its immunomodulatory therapy ImmTOR, in a phase 1 clinical trial, can reduce the level of neutralizing antibodies produced by humans against adeno-associated virus vector 8 (AAV8) by 250 times
Gene therapy usually uses AAV vectors to deliver transgenes to cells in patients.
Selecta's ImmTOR platform uses a biodegradable nanoparticle carrying the immunosuppressive drug rapamycin (rapamycin)
▲The mechanism of action of ImmTOR (picture source: Selecta Biosciences official website)
A few days ago, the company and Takeda reached a $1.
In this phase 1 clinical trial jointly conducted with AskBio, healthy volunteers received an intravenous infusion of an AAV8 vector that does not carry a transgene, or received a different dose of ImmTOR treatment while receiving an AAV8 vector infusion
The test results show:
No serious adverse events were found.
After 30 days of treatment, in volunteers treated with ImmTOR at a dose of 0.
At 30 days, among the 6 volunteers who received ImmTOR at a dose of 0.
After receiving treatment for 90 days, the neutralizing antibody titers in the volunteers treated with ImmTOR will eventually reach a level similar to that of the control group
Reference materials:
[1] Selecta Biosciences Announces Top Line Data from the Phase I SEL-399 AAV Empty Capsid Study, Highlighting Potential Benefits of ImmTOR™ in Gene Therapy.
